Our Pricing

Wegovy or Mounjaro Better? Compare UK Weight Loss Evidence

Wondering whether mounjaro or wegovy better uk suits your weight loss goals? Both are MHRA-licensed injectable treatments with impressive clinical trial data, but they work through different mechanisms and deliver different results. Our UK pharmacist team at Cured Pharmacy breaks down the evidence to help you make an informed choice with your prescriber.

How Mounjaro and Wegovy Work Differently

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK for weight management [1]. It activates two distinct hormone pathways—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)—to regulate appetite, slow gastric emptying, and improve insulin sensitivity. This dual mechanism sets it apart from single-pathway treatments.

Wegovy contains semaglutide, a GLP-1 receptor agonist that has been available in the UK since 2022 [2]. It mimics the natural GLP-1 hormone to reduce hunger signals and increase feelings of fullness. Both medications are administered once weekly via subcutaneous injection, but their receptor targets and resulting clinical effects differ significantly.

The dual-action approach of tirzepatide may explain why clinical trials have shown greater average weight loss compared to semaglutide-based treatments, though individual responses vary and both require ongoing lifestyle modifications for optimal results [1][3].

Mounjaro or Wegovy Better: Clinical Trial Evidence

The SURPASS-3 trial demonstrated that patients taking the 15mg tirzepatide dose achieved an average 22.5% body weight reduction over 72 weeks [1]. Participants on lower doses (5mg and 10mg) saw average reductions of 15.0% and 19.5% respectively. These results represent some of the highest efficacy rates recorded in obesity pharmacotherapy trials to date.

In the STEP 1 trial, adults receiving semaglutide 2.4mg (Wegovy) achieved an average 14.9% body weight reduction over 68 weeks compared to 2.4% with placebo [2]. Approximately 50% of participants lost at least 15% of their baseline weight, and one-third lost 20% or more—outcomes that exceeded previous GLP-1 treatments.

Direct head-to-head comparison came from the SURPASS-2 trial, which compared tirzepatide against semaglutide 1mg in people with type 2 diabetes [4]. While this study used a lower semaglutide dose than Wegovy's 2.4mg, tirzepatide demonstrated superior weight loss across all dose levels. However, no large-scale trial has yet directly compared tirzepatide against the full 2.4mg semaglutide dose used specifically for weight management.

What the Numbers Mean for You

Clinical trial averages don't guarantee individual results, and your response depends on factors including baseline weight, adherence to lifestyle changes, metabolic health, and tolerance to side effects. Some patients respond exceptionally well to semaglutide, while others may achieve better results with tirzepatide's dual mechanism. Your UK prescriber will assess your medical history, previous treatment responses, and clinical goals to recommend the most appropriate option during your consultation.

Side Effects and Tolerability Comparison

Both medications share similar gastrointestinal side effects due to their GLP-1 activity, including nausea, diarrhoea, constipation, and occasional vomiting [1][2]. These effects typically occur during dose escalation and often diminish over 4-8 weeks as your body adjusts. Starting at a low dose and gradually increasing every four weeks helps minimise discomfort.

In clinical trials, approximately 5-7% of tirzepatide users discontinued treatment due to adverse effects, compared to 4-7% of semaglutide users [1][2]. The rates are comparable, though some patients report that nausea feels more manageable with one medication over the other—a highly individual experience. Serious side effects are rare but can include pancreatitis, gallbladder disease, and hypoglycaemia when used with certain diabetes medications.

Neither medication is suitable for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as both carry a boxed warning based on animal studies [1][2]. Your UK prescriber will screen for contraindications during your clinical assessment to ensure safe prescribing.

UK Pricing and Availability at Cured Pharmacy

Mounjaro is available at Cured Pharmacy from £135.00 per pen, with final pricing determined by your prescribed dose following clinical assessment [5]. We guarantee the lowest UK prices and display all costs upfront before your consultation—no hidden fees or surprise charges at checkout.

Both treatments require a valid UK prescription issued after online consultation with our registered clinical team. Our assessment takes under three minutes to complete, and most patients receive a prescriber decision within 24 hours. All medications are dispensed from our UK-registered pharmacy (GPhC 9012511) and delivered in 100% discreet packaging with next-day delivery options available.

Superintendent pharmacist Tarun Kumar (GPhC 2233073) and our clinical team ensure every prescription meets MHRA safety standards and NICE guidelines. We only supply genuine UK-licensed medicines—never grey-market imports or compounded alternatives.

Transparent Pricing Guarantee

Unlike some online services that hide costs until after consultation, Cured Pharmacy shows exact pricing on every product page before you begin your assessment. This transparency helps you make informed decisions about your treatment budget without pressure or unexpected costs. Our lowest price guarantee means you won't find cheaper genuine UK-licensed Mounjaro or Wegovy elsewhere.

Which Treatment Is Right for Your Goals?

If you're seeking the highest average weight loss demonstrated in clinical trials and don't mind potentially higher costs, tirzepatide (Mounjaro) may be worth discussing with your prescriber [1][3]. Its dual-receptor mechanism has produced superior results in head-to-head diabetes trials, though direct comparison at weight-loss doses is still emerging in the literature.

If you prefer a treatment with longer real-world safety data in the UK weight management setting and competitive pricing, semaglutide (Wegovy) represents an excellent evidence-based choice [2]. It has been available for weight loss longer than tirzepatide, giving clinicians more experience managing patients on this medication.

Many patients achieve their goals with either medication when combined with reduced-calorie nutrition and increased physical activity. The 'better' option depends on your individual medical profile, budget, previous treatment history, and personal preferences. Your UK prescriber will guide this decision during your consultation, considering factors like cardiovascular risk, diabetes status, and tolerance to side effects.

Starting Your Weight Loss Treatment at Cured Pharmacy

Begin with our free online consultation, which takes less than three minutes to complete. You'll answer questions about your weight history, medical conditions, current medications, and weight loss goals. A UK-registered prescriber reviews your answers and determines whether Mounjaro, Wegovy, or an alternative treatment is clinically appropriate for you.

If approved, your prescription is sent directly to our dispensary where our GPhC-registered pharmacists prepare your medication for discreet delivery. Most orders are dispatched within 24 hours, with next-day delivery available across the UK. Each pen comes with full NHS patient information leaflets and guidance on injection technique.

Our clinical team remains available throughout your treatment for dosage adjustments, side effect management, and ongoing support. You can contact us at (+44) 116 4646009 or through your online account. We also offer repeat prescription services to ensure continuity of treatment without gaps in supply.

What to Expect During Treatment

Most prescribers start patients on the lowest dose to assess tolerance, then gradually increase every four weeks until reaching the optimal maintenance dose. You'll inject once weekly on the same day each week, rotating between injection sites (abdomen, thigh, or upper arm). Weight loss typically becomes noticeable after 4-8 weeks, with maximum effects seen after several months of consistent use alongside lifestyle modifications. Regular follow-up with your prescriber ensures safe, effective long-term management.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
4. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
5. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Public Assessment Report. GOV.UK. https://www.gov.uk/government/publications/mounjaro-tirzepatide

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary and are not guaranteed.